JP2019528279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528279A5 JP2019528279A5 JP2019508942A JP2019508942A JP2019528279A5 JP 2019528279 A5 JP2019528279 A5 JP 2019528279A5 JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019508942 A JP2019508942 A JP 2019508942A JP 2019528279 A5 JP2019528279 A5 JP 2019528279A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- cycloalkyl
- group
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CMXLWMLABMJODV-UHFFFAOYSA-N Cc(cc1C(F)(F)F)ccc1Cl Chemical compound Cc(cc1C(F)(F)F)ccc1Cl CMXLWMLABMJODV-UHFFFAOYSA-N 0.000 description 2
- OLECYYBXISHMFS-YGKWUCAESA-N CC(C)/C(/C=C(\C)/C(F)(F)F)=C(/C#C)\F Chemical compound CC(C)/C(/C=C(\C)/C(F)(F)F)=C(/C#C)\F OLECYYBXISHMFS-YGKWUCAESA-N 0.000 description 1
- RWIKZAWYMHSEOC-UHFFFAOYSA-N CC(C)c(cc1)cc(C(F)(F)F)c1F Chemical compound CC(C)c(cc1)cc(C(F)(F)F)c1F RWIKZAWYMHSEOC-UHFFFAOYSA-N 0.000 description 1
- BYPOENRTPJTXAT-UHFFFAOYSA-N CC(C)c1cccc(C(F)(F)F)c1 Chemical compound CC(C)c1cccc(C(F)(F)F)c1 BYPOENRTPJTXAT-UHFFFAOYSA-N 0.000 description 1
- HNKGOFAGRUMTEG-UHFFFAOYSA-N CCc1ccc(C(F)(F)F)c(Cl)c1 Chemical compound CCc1ccc(C(F)(F)F)c(Cl)c1 HNKGOFAGRUMTEG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376138P | 2016-08-17 | 2016-08-17 | |
| US62/376,138 | 2016-08-17 | ||
| PCT/US2017/047383 WO2018035346A1 (en) | 2016-08-17 | 2017-08-17 | Kinase inhibitor compounds, compositions, and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528279A JP2019528279A (ja) | 2019-10-10 |
| JP2019528279A5 true JP2019528279A5 (enExample) | 2020-09-17 |
Family
ID=61197083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508942A Pending JP2019528279A (ja) | 2016-08-17 | 2017-08-17 | キナーゼ阻害物質化合物、組成物、及びがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10519113B2 (enExample) |
| EP (1) | EP3500257B1 (enExample) |
| JP (1) | JP2019528279A (enExample) |
| CN (1) | CN110072526A (enExample) |
| CA (1) | CA3034332A1 (enExample) |
| WO (1) | WO2018035346A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108440404A (zh) * | 2018-05-08 | 2018-08-24 | 西安凯伦生物科技有限公司 | 具有多重激酶抑制作用的抗肿瘤药物及其制备方法和应用 |
| CN111362871B (zh) * | 2018-12-25 | 2022-05-17 | 北京福元医药股份有限公司 | 取代的吡啶-2-甲酰胺类化合物及其用途 |
| US20220387630A1 (en) | 2020-02-27 | 2022-12-08 | National University Corporation Hokkaido University | Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer |
| CN113402456B (zh) * | 2020-03-16 | 2023-03-03 | 深圳大学 | 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用 |
| AU2021268210A1 (en) * | 2020-05-08 | 2022-12-15 | Georgiamune, Inc. | Akt3 modulators |
| EP4237093A4 (en) * | 2020-11-02 | 2024-06-12 | Icahn School of Medicine at Mount Sinai | METHODS OF TREATING TUMORS AND CANCERS WITH DEREGULATED WNT SIGNALING PATHWAYS |
| KR102710925B1 (ko) * | 2021-06-01 | 2024-09-27 | 부산대학교 산학협력단 | 신규 스퀘어아마이드 유도체 및 이의 용도 |
| WO2025083280A1 (en) * | 2023-10-19 | 2025-04-24 | Universitat De Barcelona | Sorafenib analogs for use in the treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE300299T1 (de) * | 1997-12-22 | 2005-08-15 | Bayer Pharmaceuticals Corp | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
| US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| PT1580188E (pt) * | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aril-ureias como inibidores de cinases |
| WO2004014870A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| EP1608639A2 (en) * | 2003-02-28 | 2005-12-28 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| WO2004078746A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
| JP4860474B2 (ja) * | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素 |
| EP1641759B1 (en) * | 2003-07-07 | 2014-03-12 | Merck Patent GmbH | Malonamide derivatives |
| CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
| ATE395905T1 (de) * | 2004-08-27 | 2008-06-15 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
| ES2480440T3 (es) * | 2005-12-21 | 2014-07-28 | Bayer Intellectual Property Gmbh | Derivados sustituidos de pirimidina útiles en el tratamiento del cáncer y de otros trastornos |
| WO2008082730A2 (en) * | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| US20090012091A1 (en) * | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
| CN101723890B (zh) * | 2008-10-10 | 2011-11-23 | 中国科学院成都生物研究所 | 芳基硫脲及其制备方法和用途 |
| JP2011063516A (ja) * | 2009-09-15 | 2011-03-31 | Daiichi Sankyo Co Ltd | アミド誘導体 |
| WO2011046991A2 (en) * | 2009-10-15 | 2011-04-21 | Gilead Connecticut, Inc. | Certain substituted ureas as modulators of kinase activity |
| EP2675274B1 (en) * | 2011-02-14 | 2017-05-03 | The Regents of The University of California | SORAFENIB DERIVATIVES AS sEH INHIBITORS |
| US9090617B1 (en) * | 2011-08-03 | 2015-07-28 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| PL2739139T3 (pl) * | 2011-08-03 | 2020-06-15 | National Taiwan University | Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| US10449182B2 (en) * | 2012-07-06 | 2019-10-22 | The Regents Of The University Of California | Sorafenib derivatives as p21 inhibitors |
| WO2015051149A1 (en) * | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
-
2017
- 2017-08-17 US US16/325,218 patent/US10519113B2/en active Active
- 2017-08-17 JP JP2019508942A patent/JP2019528279A/ja active Pending
- 2017-08-17 CA CA3034332A patent/CA3034332A1/en active Pending
- 2017-08-17 EP EP17842133.5A patent/EP3500257B1/en active Active
- 2017-08-17 WO PCT/US2017/047383 patent/WO2018035346A1/en not_active Ceased
- 2017-08-17 CN CN201780062024.1A patent/CN110072526A/zh active Pending
-
2019
- 2019-11-14 US US16/684,159 patent/US11066370B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528279A5 (enExample) | ||
| JP2021169499A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2006501295A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2013209405A5 (enExample) | ||
| JP2020522567A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2003520195A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| RU2012137501A (ru) | Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли | |
| JPWO2021069705A5 (enExample) | ||
| JP2021046404A5 (enExample) | ||
| JP2020511547A5 (enExample) | ||
| JP2018514568A5 (enExample) | ||
| JP2017522304A5 (enExample) | ||
| RU2018133288A (ru) | Комбинированные терапии для лечения спинальной мышечной атрофии | |
| JPWO2019165358A5 (enExample) | ||
| RU2019116820A (ru) | Антагонисты интегрина | |
| JP2010505869A5 (enExample) |